0

Drug Evaluation: TAK-475--an Oral Inhibitor of Squalene Synthase for Hyperlipidemia

John R Burnett

Curr Opin Investig Drugs. 2006 Sep;7(9):850-6.

PMID: 17002264

Abstract:

Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic acid derivatives, for the potential oral treatment of hyperlipidemia. By March 2005, TAK-475 was undergoing phase III clinical trials in the US and Europe.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP189060137 TAK-475 TAK-475 189060-13-7 Price
qrcode